A combined treatment for advanced oral cavity cancers
- PMID: 3416268
- DOI: 10.1002/1097-0142(19881001)62:7<1267::aid-cncr2820620704>3.0.co;2-g
A combined treatment for advanced oral cavity cancers
Abstract
Effects of preoperative chemotherapy with three courses of a combination of bleomycin, vincristine, mitolactol, prednisone, and methotrexate, with a leucovorin rescue, followed by surgery were studied in 43 patients with advanced squamous cell carcinoma of the oral region. Before chemotherapy 34 patients (79%) had Stage III or IV carcinomas whereas nine patients had Stage II lesions. The clinical response was very encouraging: 20 patients (46%) achieved a clinical complete response and 23 patients (54%) were judged as partial responders. Side effects of this chemotherapy were minimal and reversible. Between 15 and 22 days after the last course of chemotherapy patients went to surgery. Wound healing complications did not occur. The surgical specimens were tested microscopically. The microphotographs showed small tumor rests with giant cells bordered by fibrous scar tissue and separated from the healthy tissues. With a median follow-up of 36 months (range, 21-58 months) 74% of patients are alive and 70% remain disease-free. Eleven patients died but only five (11%) because of the failure of therapy. This combined therapy appears both safe and promising treatment for advanced squamous cell carcinomas of the oral cavity. A further follow-up study needed to confirm the promising 5-year results.
Similar articles
-
An effective combined therapy for advanced squamous cell carcinoma of the oral cavity: preoperative BVMM (bleomycin, vincristine, mitolactol plus methotrexate and leucovorin) chemotherapy followed by surgery.Neoplasma. 1988;35(5):591-7. Neoplasma. 1988. PMID: 3216933
-
Neoadjuvant chemotherapy in early-stage and locally advanced small bulk squamous cell carcinoma of the oral cavity and oropharynx.Isr J Med Sci. 1988 Sep-Oct;24(9-10):539-44. Isr J Med Sci. 1988. PMID: 2462551
-
Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.Oncology. 2002;63(4):338-45. doi: 10.1159/000066226. Oncology. 2002. PMID: 12417788 Clinical Trial.
-
[Comparative study of preoperative chemotherapy and radiotherapy in squamous cell carcinoma of the oral cavity].Orv Hetil. 1992 Apr 19;133(16):961-5. Orv Hetil. 1992. PMID: 1574333 Review. Hungarian.
-
Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC).Cancer Metastasis Rev. 2010 Dec;29(4):607-11. doi: 10.1007/s10555-010-9259-7. Cancer Metastasis Rev. 2010. PMID: 20842409 Review.
Cited by
-
Neoadjuvant chemotherapy: does it have benefits for the surgeon in the treatment of advanced squamous cell cancer of the oral cavity?Pathol Oncol Res. 2010 Jun;16(2):207-12. doi: 10.1007/s12253-009-9208-3. Epub 2009 Sep 12. Pathol Oncol Res. 2010. PMID: 19757193 Clinical Trial.
-
Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties.PLoS One. 2012;7(2):e31864. doi: 10.1371/journal.pone.0031864. Epub 2012 Feb 16. PLoS One. 2012. PMID: 22359637 Free PMC article.
-
Analysis of the invasive edge in primary and secondary oral squamous cell carcinoma: An independent prognostic marker: A retrospective study.J Oral Maxillofac Pathol. 2016 May-Aug;20(2):239-45. doi: 10.4103/0973-029X.185931. J Oral Maxillofac Pathol. 2016. PMID: 27601816 Free PMC article.
-
Quercetin suppresses drug-resistant spheres via the p38 MAPK-Hsp27 apoptotic pathway in oral cancer cells.PLoS One. 2012;7(11):e49275. doi: 10.1371/journal.pone.0049275. Epub 2012 Nov 12. PLoS One. 2012. PMID: 23152886 Free PMC article.
MeSH terms
LinkOut - more resources
Medical